Log in

NASDAQ:AMAGAMAG Pharmaceuticals Stock Price, Forecast & News

-0.56 (-7.36 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: $7.05
50-Day Range
MA: $7.84
52-Week Range
Now: $7.05
Volume367,100 shs
Average Volume584,672 shs
Market Capitalization$241.60 million
P/E RatioN/A
Dividend YieldN/A
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company's products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Read More
AMAG Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.09 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AMAG



Sales & Book Value

Annual Sales$327.75 million
Book Value$8.44 per share


Net Income$-466,460,000.00
Net Margins-115.05%


Market Cap$241.60 million
Next Earnings Date8/5/2020 (Estimated)

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

How has AMAG Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

AMAG Pharmaceuticals' stock was trading at $6.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMAG stock has increased by 6.5% and is now trading at $7.05. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AMAG Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AMAG Pharmaceuticals.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for AMAG Pharmaceuticals.

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) posted its quarterly earnings data on Monday, May, 11th. The specialty pharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.27. The specialty pharmaceutical company earned $68.66 million during the quarter, compared to the consensus estimate of $64.95 million. AMAG Pharmaceuticals had a negative net margin of 115.05% and a negative return on equity of 28.28%. View AMAG Pharmaceuticals' earnings history.

What price target have analysts set for AMAG?

7 Wall Street analysts have issued twelve-month price targets for AMAG Pharmaceuticals' shares. Their forecasts range from $6.00 to $11.00. On average, they anticipate AMAG Pharmaceuticals' share price to reach $8.29 in the next year. This suggests a possible upside of 17.5% from the stock's current price. View analysts' price targets for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AMAG's drug Feraheme continues to perform well. The company’s pipeline consists of promising development-stage assets. In January 2020, the company acknowledged the Makena challenges during its strategic review, resulting in the decision to divest Intrarosa and Vyleesi two sexual health treatments for women. decision will position the company well to focus on e continuing the development of its pipeline candidates ciraparantag and AMAG-423, see continued growth of Feraheme, and carry on with its work to retain patient access to Makena. Shares of the company have underperformed the industry year to date. Estimates have gone down ahead of Q1 earnings release. AMAG has a negative record of earnings surprises in the recent quarters." (5/6/2020)
  • 2. HC Wainwright analysts commented, "Our $16 price target for AMAG is based on our sum-of-the-parts NPV valuation based on each of the company’s assets; we value the company’s commercail assets, and pipeline assets, ciraparantag ($9.07) and AMG-423 ($1.75) and deduct unallocated R&D and corporate expenses ($10.78). We have negligible value for Intrarosa and MuGard. Our valuation model utilizes a discount rate of 10.4% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%). We adjust each pipeline indication for probability of success with ciraparantag at 50% (adjusting for risk of ultimate approval as well as probability of establishing differentiated profile); and AMAG-423 at 33%." (8/8/2019)

Has AMAG Pharmaceuticals been receiving favorable news coverage?

News articles about AMAG stock have trended somewhat negative this week, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about AMAG Pharmaceuticals.

Who are some of AMAG Pharmaceuticals' key competitors?

What other stocks do shareholders of AMAG Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Palatin Technologies (PTN), Bausch Health Companies (BHC), Broadcom (AVGO), Energy Transfer LP Unit (ET), Netflix (NFLX), NVIDIA (NVDA), Ford Motor (F) and Skyworks Solutions (SWKS).

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the following people:
  • Dr. William K. Heiden, CEO, Pres & Director (Age 59)
  • Mr. Edward H. Myles, Exec. VP, CFO & Treasurer (Age 47)
  • Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Corp. Sec. (Age 47)
  • Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 53)
  • Ms. Linda S. Lennox, VP of Investor Relations & Corp. Communications

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $7.05.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $241.60 million and generates $327.75 million in revenue each year. The specialty pharmaceutical company earns $-466,460,000.00 in net income (profit) each year or ($6.88) on an earnings per share basis. AMAG Pharmaceuticals employs 467 workers across the globe.

What is AMAG Pharmaceuticals' official website?

The official website for AMAG Pharmaceuticals is www.amagpharma.com.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.